Navigation Links
SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor
Date:11/20/2008

DUBLIN, Calif., Nov. 20 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it has received clearance to initiate clinical trials with SGI-1776, an inhibitor of Pim kinases. The clearance of its Original Investigational New Drug Application ("IND") triggers a $5.2 million milestone payment to the former stockholders of Montigen Pharmaceuticals, Inc. The milestone payment will consist of $2.8 million in cash payments and the issuance of approximately $2.4 million in equity, representing approximately 1.5 million shares of SuperGen common stock.

SuperGen will initiate a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic profile of SGI-1776, a novel, orally administered, small molecule anticancer compound. The first in human clinical trial program will enroll patients with solid tumors with specific emphasis on hormone refractory prostate cancer and refractory non-Hodgkin's lymphomas. These solid tumor types have been reported to overexpress the Pim kinase family of proteins at a high frequency. Overexpression of Pim-1 kinase has been shown to be a marker of poor prognosis in these tumors. A second Phase I/II study is being planned in patients with refractory leukemias in which Pim kinases are also overexpressed, and correlated with poor prognosis and drug resistance.

"We are pleased to acknowledge FDA's clearance of our IND application to enter what we believe is the world's first investigational product targeted to inhibit PIM kinases into Phase I clinical trials," said Dr. James Manuso, SuperGen's President and Chief Executive Officer. "The clearance of the SGI-1776 IND application represents a validation of our Company's CLIMB(TM) technology platform and its ability to
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SuperGen Reports 2008 Third Quarter Financial Results
2. SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008
3. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
4. SuperGen to Present Data at EORTC-NCI-AACR
5. SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008
6. SuperGen Reports 2008 Second Quarter Financial Results
7. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
8. SuperGen Reports 2008 First Quarter Financial Results
9. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
10. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
11. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: the ... expertly narrows down the mass of product choices to ... , First, select the working environment, then enter ... and define the accuracy – it’s really that simple. ... list to models that fit best with the customer’s ...
(Date:7/24/2014)... Brook, NJ (PRWEB) July 24, 2014 ... to manage numerous projects in the MENA region during ... to have a preferred provider agreement with DZS to ... the MENA region,” said Global VP of R&D and ... "DZS has developed excellent operational practices with a focus ...
(Date:7/23/2014)... in saving China,s endangered national treasure, the giant panda. ... reserves that have been established and three large breeding ... in the wild. , Breeding programs in conservation ... improving genetic diversity, avoid inbreeding and ultimately, introduce pandas ... programs doing so far? , In a new study ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... VRUS ) management will present at the Third Annual ... 2008 at the Le,Parker Meridien in New York City. ... of the company on Monday,October 6, 2008, from 10:00-10:30 ... Mr. Price,s overview via the internet, log,on to the ...
... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
... confirms implementation of quality systems in product ... ... function assay, COLUMBIA, Md., Oct. 1 Cylex ... The 13485:2003 certification,includes compliance with the Canadian Medical Devices ...
Cached Biology Technology:Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th 2Cylex(TM) Receives ISO 13485:2003 and 9001:2000 Quality Certifications 2
(Date:7/24/2014)... affect the connections between nerve cells and influence the ... of the brain that plays a significant role in ... of the study have been published in the journal ... active communication between nerve cells, known as neurons. For ... network where they constantly relay signals to one another. ...
(Date:7/24/2014)... hazard in the United States, wildland managers often utilize ... suppressed trees (ladder fuels). These cuttings and other ... fire danger in order to dispose of the material. ... managers often cover all or part of the debris ... agricultural plastic, in order to keep water out. A ...
(Date:7/24/2014)... currently conducting research into the potato genes that best ... a reduction in rainfall and increased extremes of hot ... resistant genes in order to create new potato varieties ... is also seeking to find out how the current ... drought and higher and lower temperatures. , This research ...
Breaking Biology News(10 mins):A protein couple controls flow of information into the brain's memory center 2A protein couple controls flow of information into the brain's memory center 3A protein couple controls flow of information into the brain's memory center 4Study gives new perspective on agricultural plastic, debris burning, and air quality 2Neiker-Tecnalia is researching the potato genes that best adapt to climate change 2
... A University of Sheffield academic is helping a team ... European genetic heritage. Citizen Scientists are not required ... they possess a passion for the subject and are ... involved in research. Dr Andy Grierson, from the ...
... Researchers could have a new method to rebuild wetlands ... monitoring severe flooding of the Mississippi River. A team ... in collaboration with the U.S. Army Corps of Engineers, published ... In the spring and summer of 2011, high floodwaters on ...
... While some published research has hinted at the connection ... among young, athletic African-American males, which was initially observed ... study with the first sizeable patient series definitively confirms ... The sickle cell trait, for which all U.S. African ...
Cached Biology News:Citizen science helps unlock European genetic heritage 2Citizen science helps unlock European genetic heritage 3Spillways can divert sand from river to rebuild wetlands 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3
... • Heat activated ,• Eliminates ... temperature ,• Excellent specificity allows extension ... secondary structures ,• Leaves an 'A' ... modified form of GeneChoice DNA Polymerase ...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits allseven ... channel tip cone modules. ...
...
Biology Products: